Anika Therapeutics, Inc.
ANIK- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000898437
In the last 90 days, Anika Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 133 institutions reported holding it in 13F filings for Q2 2026, worth $179.0M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Anika Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $41.1K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$41.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Anika Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Fishetti Gary P | Director | 54,015 | Aug 5, 2026 | 2 |
| Henneman John B III | Director | 65,273 | Jun 23, 2026 | 2 |
| Conley Sheryl L | Director | 52,970 | Jun 23, 2026 | 1 |
| Capper Joseph H | Director | 30,805 | Jun 23, 2026 | 1 |
| Richard Stephen | Director | 58,273 | Jun 23, 2026 | 1 |
| Griffin Stephen D. | President and CEO | 45,973 | Jun 5, 2026 | 4 |
| McLeod Ian | SVP, CAO & Treasurer | 24,107 | Mar 23, 2026 | 3 |
| Blanchard Cheryl R | Director | 258,788 | Mar 17, 2026 | 2 |
| Colleran David | EVP, General Counsel, Corp Sec | 67,570 | Mar 17, 2026 | 2 |
| Jellison William R | Director | 20,403 | Jun 24, 2025 | 0 |
| Vogt Susan L N | Director | 50,213 | Jun 24, 2025 | 0 |
| Larsen Glenn R. | Director | 50,258 | Jun 24, 2025 | 0 |
| Nunes Anne | SVP, Chief Operations Officer | 20,654 | Mar 18, 2025 | 0 |
| Levitz Michael L | EVP, CFO, Treasurer | 46,955 | Mar 19, 2024 | 0 |
| Thompson Jeffery S | Director | 31,575 | Jun 16, 2023 | 0 |
| Finnerty Thomas | EVP, Human Resources | 24,598 | Mar 11, 2022 | 0 |
| Loerop James | EVP Business Development | 5,592 | Jul 12, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2026 (view filing)4:30 PM ET | Aug 3-4 | 2 days | Fishetti Gary PDirector | PPurchase | +2.00K | $20.53 | +$41.1K | +3.8%54.0K after | 2 lots |
| May 4, 2026 (view filing) | May 1 | 3 days | Henneman John B IIIDirector | PPurchase | +5.00K | $14.66 | +$73.3K | +10.0%54.9K after | |
| Apr 30, 2026 (view filing) | Apr 30 | Same day | Griffin Stephen D.President and CEO | PPurchase | +12.2K | $12.29 | +$149.9K | +50.9%36.2K after | |
| May 12, 2022 (view filing) | May 11 | 1 day | Colleran DavidEVP, General Counsel, Corp Sec | PPurchase | +1.50K | $21.37 | +$32.1K | +17.9%9.87K after | |
| Mar 16, 2022 (view filing) | Mar 14 | 2 days | Colleran DavidEVP, General Counsel, Corp Sec | PPurchase | +1.50K | $26.65 | +$40.0K | +21.8%8.37K after | |
| Mar 15, 2022 (view filing) | Mar 11 | 4 days | Thompson Jeffery SDirector | PPurchase | +2.00K | $24.66 | +$49.3K | +13.2%17.1K after | |
| Mar 14, 2022 (view filing) | Mar 11 | 3 days | Blanchard Cheryl RPresident, CEO, Director | PPurchase | +8.10K | $25.57 | +$207.1K | +15.6%60.0K after | 2 lots |
| Mar 14, 2022 (view filing) | Mar 11 | 3 days | Levitz Michael LEVP, CFO, Treasurer | PPurchase | +4.00K | $24.62 | +$98.5K | +33.5%15.9K after | |
| Aug 13, 2021 (view filing) | Aug 11-12 | 2 days | Levitz Michael LEVP, CFO, Treasurer | PPurchase | +3.63K | $40.21 | +$145.8K | +94.0%7.49K after | 2 lots |